Seongnam-si, South Korea

Hyun-Tak Jin

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hyun-Tak Jin: Innovator in Cervical Cancer Treatment

Introduction

Hyun-Tak Jin is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of medical treatment, particularly in addressing cervical cancer caused by human papillomavirus (HPV) infection. His innovative approach aims to improve treatment methods for this serious health issue.

Latest Patents

Hyun-Tak Jin holds 1 patent related to his work. His patent, titled "Methods of treating cervical cancer," focuses on enhancing the treatment of cervical tumors associated with HPV infection. The invention provides methods for utilizing a polynucleotide encoding an E6/E7 fusion protein to improve treatment outcomes for patients suffering from this condition.

Career Highlights

Hyun-Tak Jin is currently associated with Genexine, Inc., a company dedicated to developing innovative biopharmaceuticals. His work at Genexine reflects his commitment to advancing medical science and improving patient care through innovative treatments.

Collaborations

Throughout his career, Hyun-Tak Jin has collaborated with esteemed colleagues, including Hye Seong Lim and You Suk Suh. These collaborations have contributed to the development of effective treatment methods and have fostered a spirit of innovation within the field.

Conclusion

Hyun-Tak Jin's contributions to cervical cancer treatment exemplify the impact of innovation in medicine. His dedication to improving patient outcomes through his patented methods highlights the importance of research and collaboration in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…